Ariel Grajales-Cruz

10PUBLICATIONS
105CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 02, 2026
Plasmablastic Richter Transformation of Chronic Lymphocytic Leukemia With Aberrant Epithelial Marker Expression Presenting as a Pleural Effusion: A Diagnostic Challenge.

|Jun 11, 2026
Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma.

|Aug 01, 2025
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

Binod Dhakal, Othman S Akhtar, David Fandrei

|Jul 09, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

|Apr 08, 2025
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.

Danai Dima, Aimaz Afrough, Utkarsh Goel

|Dec 09, 2024
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes.

Ciara L Freeman, Jerald Noble, Meghan Menges

Pageof 2

Frequent Collaborators

5 joint publications

Doris K Hansen

5 joint publications

Omar Castaneda Puglianini

4 joint publications

Larry D Anderson

4 joint publications

Danai Dima